Dermatitis Herpetiformis
Definition
Dermatitis herpetiformis (DH), also known as Duhring’s disease, is a chronic autoimmune blistering skin disorder characterized by persistent pruritus and grouped, symmetrical lesions typically affecting the elbows, knees, scalp, and buttocks.
First described by Louis Duhring in 1884, the condition is strongly associated with gluten intolerance and is considered a specific cutaneous manifestation of celiac disease.
• Subspecialty care, extensive experience, and advanced scientific training
• Comprehensive and effective treatment approaches
• Maximum therapeutic efficacy
• Minimal to no side effects
Dermatitis Herpetiformis and Celiac Disease
Celiac disease is a chronic autoimmune enteropathy triggered by the ingestion of gluten-containing foods. Exposure to gluten provokes an immune-mediated response marked by the production of IgA and IgG autoantibodies, which target and damage the mucosa of the small intestine, leading to malabsorption.
Typical manifestations include altered bowel habits, abdominal pain, bloating, stunted growth, osteopenia, and anemia.
DH is considered the most specific extraintestinal manifestation of gluten sensitivity, present in up to 90% of individuals with celiac disease, often preceding or paralleling intestinal symptoms.
Clinical Features of Dermatitis Herpetiformis
The disease typically begins with intense pruritus and inflammatory skin changes. Patients often develop erythematous papulovesicular eruptions, grouped vesicles, and occasionally urticarial plaques. Lesions are symmetrically distributed and may appear in a circular configuration.
Initial involvement includes the scalp and forehead, with progression to the chest, shoulders, arms, elbows, back, buttocks, and knees.
Ruptured vesicles give rise to painful erosions and ulcers, which often heal with residual post-inflammatory hyperpigmentation.
Blisters usually occur in clusters. Due to the intense itching, excoriations and even bleeding may be observed, which may lead to scarring.
The rash varies morphologically, presenting as papular, vesicular, bullous, or urticarial. In some cases, petechial lesions appear on the fingers or palms.
The clinical course is typically relapsing-remitting and may fluctuate with hormonal changes such as perimenopause.
Exacerbating Factors
Certain agents have been implicated in exacerbating DH, including iodine and iodine-based contrast media used in radiological studies, oral cough syrups, and seafood such as fish and shellfish.
Diagnosis
Early-stage diagnosis can be challenging, as DH may be misdiagnosed as eczema or erythema multiforme. Definitive diagnosis relies on the detection of IgA deposits at the dermoepidermal junction via skin biopsy and direct immunofluorescence microscopy.
Small intestinal biopsy is also necessary to confirm underlying celiac disease and assess mucosal damage.
Immunofluorescence plays a pivotal role in diagnosis. Both direct and indirect immunofluorescence techniques are used to confirm the presence of dermal IgA deposition and circulating autoantibodies.
Direct immunofluorescence requires a perilesional skin sample, while indirect methods involve serological testing for IgA-class antibodies. Once confirmed, patients should be screened for gluten-sensitive enteropathy.
Treatment
The cornerstone of management is strict, lifelong adherence to a gluten-free diet. Symptomatic control can often be achieved with gluten elimination, supplemented by topical corticosteroids and antihistamines for pruritus relief.
It is critical that patients permanently avoid dietary sources of gluten—namely wheat, barley, and rye—to prevent disease flares.
After sustained remission, occasional incidental gluten exposure may not trigger relapse in all patients, but this must be approached cautiously.
In cases of widespread, refractory, or relapsing disease, systemic therapy may be required. First-line agents include oral dapsone, sulfapyridine, or systemic corticosteroids.
Recent case reports from international centers indicate promising outcomes with rituximab in resistant forms.
Ultimately, treatment must be individualized, taking into account the clinical severity, patient preferences, and overall immune status.